Yaacob NS, Kamal NNNM, Norazmi MN. Synergistic anticancer effects of a bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines. BMC Complementary and Alternative Medicine 1-13. 2014.
Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapesCancer Cell 34: 256-70 2018.
Frenel J-S, Tourneau CL, Neil BO. Safety and efficacy of pembrolizumab
in advanced, programmed death ligand 1-positive cervical
cancer: Results from the phase Ib KEYNOTE-028 trial. J Clin
Oncol 35: 4035-41.2017
Ott PA, Bang Y-J, Berton-Rigaud D. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35: 4035-41.2017;  Ott PA, Bang Y-J, Berton-Rigaud D. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1- positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol 35: 2535-41. 2017.
Zhang X, Xiong G, Zhou Y, et al. Expression of HDAC4 in hepatocellular carcinoma and its correlation with prognosis. Int J Clin Exp Pathol 2016; 9: 12171-7.
Wang L-T, Liou J-P, Li Y-H, et al. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/ PKCδ and E-cadherin. Oncotarget 5: 5651-62. 2014.
Infante JR, Mendelson DS. , III HAB, et al. A first-in-human doseescalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Invest New Drugs 34: 216- 24. 2016.
Park K, Tan E-H, O’Byrne K. Afatinib versus gefitinib as fi rst-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised. Lancet Oncol 577-89. 2016.
Azambuja Ed, Holmes AP, Piccart-Gebhart M. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncology 15: 1137-46.2014;
Graaf WTAvd, Blay J-Y, Chawla SP. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 379: 1879-86. 2012.
Yazbeck V, Shafer D, Perkins EB, et al. A phase ii trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large b-cell lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18(9): 569-75.